UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012613
Receipt number R000014747
Scientific Title Reduction or withdrawal of etanercept after remission with etanerceptin patients with rheumatoid arthritis patients.
Date of disclosure of the study information 2013/12/20
Last modified on 2013/12/17 21:46:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Reduction or withdrawal of etanercept after remission with etanerceptin patients with rheumatoid arthritis patients.

Acronym

Reduction of etanercept after remission in RA patients.

Scientific Title

Reduction or withdrawal of etanercept after remission with etanerceptin patients with rheumatoid arthritis patients.

Scientific Title:Acronym

Reduction of etanercept after remission in RA patients.

Region

Japan


Condition

Condition

rheumatoid arthritis

Classification by specialty

Clinical immunology Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study was to assess whether remission would be sustained with reduced doses or withdrawal of etanercept in patients with rheumatoid arthritis after clinical remission. Additionally, investigation of optimum use of biologics also was the aim of this study.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

activity score of rheumatoid arthritis: DAS(Disease Activity Score),swollen joint count, tender joint cont, ESR, patient VAS, CRP

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

etanercept50mg/wk or25mg twice/wk
reduction of etanercept to 25mg/wk arfter 3 months from remission

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >

Gender

Male and Female

Key inclusion criteria

patients within remission stage(DAS28 under 2.6) after etanercept50mg/wk or25mg twice/wk

Key exclusion criteria

patients withoout remission stage(DAS28 under 2.6) after etanercept50mg/wk or25mg twice/wk

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Mikio Nakajima

Organization

Osaka Medical College

Division name

Dept. of orthopedic surgery

Zip code


Address

Daigakumachi 2-7, Takatsuki, OSAKA

TEL

072-683-1221

Email

ort054@poh.osaka-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Mikio Nakajima

Organization

Osaka Medical College

Division name

Dept. of orthopedic surgery

Zip code


Address

Daigakumachi 2-7, Takatsuki, OSAKA

TEL

072-683-1221

Homepage URL


Email

ort054@poh.osaka-med.ac.jp


Sponsor or person

Institute

Dept. of orthopedic surgery, Osaka Medical College

Institute

Department

Personal name



Funding Source

Organization

Dept. of orthopedic surgery, Osaka Medical College

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 12 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 10 Month 28 Day

Date of IRB


Anticipated trial start date

2012 Year 01 Month 01 Day

Last follow-up date

2013 Year 09 Month 30 Day

Date of closure to data entry

2013 Year 09 Month 30 Day

Date trial data considered complete

2013 Year 09 Month 30 Day

Date analysis concluded

2013 Year 09 Month 30 Day


Other

Other related information



Management information

Registered date

2013 Year 12 Month 17 Day

Last modified on

2013 Year 12 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014747


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name